Skip to main navigation Skip to search Skip to main content

Potent immune modulation by medi6383, an engineered human ox40 ligand igg4p fc fusion protein

  • Michael D. Oberst
  • , Catherine Auge
  • , Chad Morris
  • , Stacy Kentner
  • , Kathy Mulgrew
  • , Kelly McGlinchey
  • , James Hair
  • , Shino Hanabuchi
  • , Qun Du
  • , Melissa Damschroder
  • , Hui Feng
  • , Steven Eck
  • , Nicholas Buss
  • , Lolke de Haan
  • , Andrew J. Pierce
  • , Haesun Park
  • , Andrew Sylwester
  • , Michael K. Axthelm
  • , Louis Picker
  • , Nicholas P. Morris
  • Andrew Weinberg, Scott A. Hammond

Research output: Contribution to journal › Article › peer-review

40 Scopus citations

Abstract

Ligation of OX40 (CD134, TNFRSF4) on activated T cells by its natural ligand (OX40L, CD252, TNFSF4) enhances cellular survival, proliferation, and effector functions such as cytokine release and cellular cytotoxicity. We engineered a recombinant human OX40L IgG4P Fc fusion protein termed MEDI6383 that assembles into a hexameric structure and exerts potent agonist activity following engagement of OX40. MEDI6383 displayed solution-phase agonist activity that was enhanced when the fusion protein was clustered by Fc gamma receptors (FcgRs) on the surface of adjacent cells. The resulting costimulation of OX40 on T cells induced NFkB promoter activity in OX40-expressing T cells and induced Th1-type cytokine production, proliferation, and resistance to regulatory T cell (Treg)mediated suppression. MEDI6383 enhanced the cytolytic activity of tumor-reactive T cells and reduced tumor growth in the context of an alloreactive human T cell:tumor cell admix model in immunocompromised mice. Consistent with the role of OX40 costimulation in the expansion of memory T cells, MEDI6383 administered to healthy nonhuman primates elicited peripheral blood CD4 and CD8 central and effector memory T-cell proliferation as well as B-cell proliferation. Together, these results suggest that OX40 agonism has the potential to enhance antitumor immunity in human malignancies.

Original languageEnglish
Pages (from-to)1024-1038
Number of pages15
JournalMolecular Cancer Therapeutics
Volume17
Issue number5
DOIs
StatePublished - May 2018

Fingerprint

Dive into the research topics of 'Potent immune modulation by medi6383, an engineered human ox40 ligand igg4p fc fusion protein'. Together they form a unique fingerprint.

Cite this